Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/8942774/ below:

Randomised study of screening for colorectal cancer with faecal-occult-blood test

Clinical Trial

Affiliations

• ¹ Department of Surgery A, Odense University Hospital, Denmark.

• PMID: 8942774
• DOI: 10.1016/S0140-6736(96)03430-7

Item in Clipboard

Clinical Trial

O Kronborg et al. Lancet. 1996.

• ¹ Department of Surgery A, Odense University Hospital, Denmark.

• PMID: 8942774
• DOI: 10.1016/S0140-6736(96)03430-7

Item in Clipboard

Background: Case-control studies and a voluntary-based follow-up study have suggested that repeated screening with faecal-occult-blood (FOB) tests can lead to a reduction in mortality from colorectal cancer (CRC). The aim of this randomised study was to compare mortality rates after FOB tests every 2 years during a 10-year period with those of unscreened similar controls.

Methods: 140,000 people aged 45-75 years lived in Funen, Denmark, in August, 1985, and were considered for inclusion in our study. Before randomisation we excluded individuals who had CRC or precursor adenomas and those who had taken part in a previous pilot study. Randomisation of 137,485 people in blocks of 14 allocated three per 14 to the screening group (30,967), three per 14 to the control group (30,966), and eight not to be enrolled in the study (75,552). Controls were not told about the study and continued to use health-care facilities as normal. Hemoccult-II blood tests (with dietary restrictions but without rehydration) were sent to screening-group participants. Only those participants who completed the first screening round were invited for further screening--five rounds of screening during a 10-year period. Participants with positive tests were asked to attend to full examination and were offered colonoscopy whenever possible. The primary endpoint was death from CRC.

Findings: Of the 30,967 screening-group participants, 20,672 (67%) completed the first screening round and were invited for further screening; more than 90% accepted repeated screenings. During the 10-year study, 481 people in the screening group had a diagnosis of CRC, compared with 483 unscreened controls. There were 205 deaths attributable to CRC in the screening group, compared with 249 deaths in controls. CRC mortality, including deaths attributable to complications from CRC treatment, was significantly lower in the screening group than in controls (mortality ratio 0.82 [95% CI 0.68-0.99]) p = 0.03).

Interpretation: Our findings indicate that biennial screening by FOB tests can reduce CRC mortality. This study is being continued to improve its statistical power and to assess the effect of the removal of more precursor adenomas in the screening-group participants than in controls on CRC incidence.

PubMed Disclaimer

• ACP J Club. 1997 May-Jun;126(3):62-3
• Screening for colorectal cancer.

  Gøtzsche P. Gøtzsche P. Lancet. 1997 Feb 1;349(9048):356; author reply 358. doi: 10.1016/S0140-6736(05)62854-1. Lancet. 1997. PMID: 9024398 No abstract available.

• Screening for colorectal cancer.

  Budenholzer B. Budenholzer B. Lancet. 1997 Feb 1;349(9048):356-7; author reply 358. doi: 10.1016/S0140-6736(05)62855-3. Lancet. 1997. PMID: 9024399 No abstract available.

• Screening for colorectal cancer.

  Lijmer JG, Bossuyt PM. Lijmer JG, et al. Lancet. 1997 Feb 1;349(9048):357; author reply 358. doi: 10.1016/S0140-6736(05)62856-5. Lancet. 1997. PMID: 9024400 No abstract available.

• Screening for colorectal cancer.

  John MR, Schmidt-Gayk H, Sieg A. John MR, et al. Lancet. 1997 Feb 1;349(9048):357-8. doi: 10.1016/S0140-6736(05)62857-7. Lancet. 1997. PMID: 9024401 No abstract available.

• Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

  Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Hardcastle JD, et al. Lancet. 1996 Nov 30;348(9040):1472-7. doi: 10.1016/S0140-6736(96)03386-7. Lancet. 1996. PMID: 8942775 Clinical Trial.

• [Randomized population study of screening for intestinal cancer with Hemoccult-II].

  Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Kronborg O, et al. Ugeskr Laeger. 1997 Aug 11;159(33):4977-81. Ugeskr Laeger. 1997. PMID: 9281212 Clinical Trial. Danish.

• Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.

  Kronborg O, Jørgensen OD, Fenger C, Rasmussen M. Kronborg O, et al. Scand J Gastroenterol. 2004 Sep;39(9):846-51. doi: 10.1080/00365520410003182. Scand J Gastroenterol. 2004. PMID: 15513382 Clinical Trial.

• Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

  Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Hewitson P, et al. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD001216. doi: 10.1002/14651858.CD001216.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253456 Free PMC article. Review.

• Screening for colorectal cancer using the faecal occult blood test, hemoccult. Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J. Towler BP, et al. Cochrane Database Syst Rev. 2000;(2):CD001216. doi: 10.1002/14651858.CD001216. Cochrane Database Syst Rev. 2000. PMID: 10796760 Updated. Review.

• Low Rates of Colonoscopy Follow-up After a Positive Fecal Immunochemical Test in a Medicaid Health Plan Delivered Mailed Colorectal Cancer Screening Program.

  Green BB, Baldwin LM, West II, Schwartz M, Coronado GD. Green BB, et al. J Prim Care Community Health. 2020 Jan-Dec;11:2150132720958525. doi: 10.1177/2150132720958525. J Prim Care Community Health. 2020. PMID: 32912056 Free PMC article.

• 3 liters of polyethylene glycol vs. standard bowel preparation have equal efficacy in a Chinese population: a randomized, controlled trial.

  Cheng P, Chen Q, Li J, Pang L, Feng C, Wang N, Bai Y, Li Z, Meng X. Cheng P, et al. Am J Transl Res. 2022 Aug 15;14(8):5641-5650. eCollection 2022. Am J Transl Res. 2022. PMID: 36105041 Free PMC article.

• Korean guidelines for colorectal cancer screening and polyp detection.

  Lee BI, Hong SP, Kim SE, Kim SH, Kim HS, Hong SN, Yang DH, Shin SJ, Lee SH, Park DI, Kim YH, Kim HJ, Yang SK, Kim HJ, Jeon HJ; Multi-Society Task Force for Development of Guidelines for Colorectal Polyp Screening, Surveillance and Management. Lee BI, et al. Clin Endosc. 2012 Mar;45(1):25-43. doi: 10.5946/ce.2012.45.1.25. Epub 2012 Mar 31. Clin Endosc. 2012. PMID: 22741131 Free PMC article.

• Patient willingness for repeat screening and preference for CT colonography and optical colonoscopy in ACRIN 6664: the National CT Colonography trial.

  Gareen IF, Siewert B, Vanness DJ, Herman B, Johnson CD, Gatsonis C. Gareen IF, et al. Patient Prefer Adherence. 2015 Jul 23;9:1043-51. doi: 10.2147/PPA.S81901. eCollection 2015. Patient Prefer Adherence. 2015. PMID: 26229451 Free PMC article.

• Impact of fecal occult blood on obscure gastrointestinal bleeding: observational study.

  Kobayashi Y, Watabe H, Yamada A, Suzuki H, Hirata Y, Yamaji Y, Yoshida H, Koike K. Kobayashi Y, et al. World J Gastroenterol. 2015 Jan 7;21(1):326-32. doi: 10.3748/wjg.v21.i1.326. World J Gastroenterol. 2015. PMID: 25574108 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3